BrightPath Biotherapeutics Co., Ltd. (4594.T)
JPY 40.0
(11.11%)
JPY 40.0
(11.11%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.16 Billion JPY | 20.75% |
| 2022 | -1.46 Billion JPY | -0.73% |
| 2021 | -1.44 Billion JPY | 14.29% |
| 2020 | -1.65 Billion JPY | 2.4% |
| 2019 | -1.76 Billion JPY | -25.26% |
| 2018 | -1.58 Billion JPY | 7.27% |
| 2017 | -1.48 Billion JPY | -39.05% |
| 2016 | -1.07 Billion JPY | -9.94% |
| 2015 | -973.67 Million JPY | -140.59% |
| 2014 | -399.63 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -326.97 Million JPY | -54.36% |
| 2023 Q2 | -257.13 Million JPY | 11.95% |
| 2023 Q1 | -292.02 Million JPY | -10.08% |
| 2023 Q3 | -393.24 Million JPY | -52.93% |
| 2023 FY | - JPY | 20.75% |
| 2023 Q4 | -207.82 Million JPY | 47.15% |
| 2022 Q4 | -265.3 Million JPY | 35.81% |
| 2022 Q3 | -413.3 Million JPY | -59.18% |
| 2022 FY | - JPY | -0.73% |
| 2022 Q2 | -259.64 Million JPY | 52.4% |
| 2022 Q1 | -545.42 Million JPY | -33.45% |
| 2021 Q3 | -350.66 Million JPY | -10.23% |
| 2021 Q1 | -404.09 Million JPY | 9.42% |
| 2021 Q4 | -408.69 Million JPY | -16.55% |
| 2021 Q2 | -318.12 Million JPY | 21.27% |
| 2021 FY | - JPY | 14.29% |
| 2020 Q4 | -446.11 Million JPY | 16.13% |
| 2020 FY | - JPY | 2.4% |
| 2020 Q1 | -406.98 Million JPY | 14.92% |
| 2020 Q2 | -369.22 Million JPY | 9.28% |
| 2020 Q3 | -531.91 Million JPY | -44.06% |
| 2019 Q2 | -420.62 Million JPY | 1.91% |
| 2019 Q4 | -478.34 Million JPY | -3.16% |
| 2019 Q1 | -428.83 Million JPY | -13.67% |
| 2019 Q3 | -463.67 Million JPY | -10.23% |
| 2019 FY | - JPY | -25.26% |
| 2018 FY | - JPY | 7.27% |
| 2018 Q4 | -377.26 Million JPY | 16.61% |
| 2018 Q3 | -452.42 Million JPY | -8.08% |
| 2018 Q2 | -418.58 Million JPY | -94.83% |
| 2018 Q1 | -214.84 Million JPY | 45.22% |
| 2017 Q1 | -262.07 Million JPY | 36.75% |
| 2017 Q2 | -423.84 Million JPY | -61.73% |
| 2017 Q3 | -483.6 Million JPY | -14.1% |
| 2017 Q4 | -392.2 Million JPY | 18.9% |
| 2017 FY | - JPY | -39.05% |
| 2016 FY | - JPY | -9.94% |
| 2016 Q3 | -230.37 Million JPY | 17.98% |
| 2016 Q2 | -280.88 Million JPY | -49.44% |
| 2016 Q1 | -187.95 Million JPY | 6.48% |
| 2016 Q4 | -414.34 Million JPY | -79.86% |
| 2015 FY | - JPY | -140.59% |
| 2015 Q4 | -200.98 Million JPY | -8.48% |
| 2015 Q3 | -185.26 Million JPY | 41.42% |
| 2015 Q1 | -290.42 Million JPY | 0.0% |
| 2015 Q2 | -316.28 Million JPY | -8.91% |
| 2014 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 221.677% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | -138.826% |
| GNI Group Ltd. | 14.48 Billion JPY | 108.046% |
| Linical Co., Ltd. | 1.24 Billion JPY | 193.47% |
| Trans Genic Inc. | 240.95 Million JPY | 583.825% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 14.018% |
| Soiken Holdings Inc. | -583.2 Million JPY | -99.893% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | -93.302% |
| AnGes, Inc. | -8.86 Billion JPY | 86.842% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 9.312% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 84.244% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 1010.01% |
| NanoCarrier Co., Ltd. | -863 Million JPY | -35.085% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | -6.778% |
| CanBas Co., Ltd. | 53.65 Million JPY | 2272.906% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | -50.309% |
| RaQualia Pharma Inc. | -111.8 Million JPY | -942.733% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | 3.792% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 15.573% |
| PeptiDream Inc. | 7.37 Billion JPY | 115.805% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 39.587% |
| Ribomic Inc. | -1.01 Billion JPY | -15.136% |
| SanBio Company Limited | -4.52 Billion JPY | 74.237% |
| Healios K.K. | -3 Billion JPY | 61.231% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 16.315% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 16.848% |
| StemRIM | -2.03 Billion JPY | 42.629% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 189.234% |
| FunPep Company Limited | -952 Million JPY | -22.457% |
| Kringle Pharma, Inc. | -888.76 Million JPY | -31.17% |
| Stella Pharma Corporation | -723.85 Million JPY | -61.053% |
| TMS Co., Ltd. | -937 Million JPY | -24.417% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -50.348% |
| Cuorips Inc. | -518 Million JPY | -125.055% |
| K Pharma,Inc. | 366.05 Million JPY | 418.47% |
| Takara Bio Inc. | 8.02 Billion JPY | 114.529% |
| ReproCELL Incorporated | 8.24 Million JPY | 14239.309% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 1425.691% |
| StemCell Institute Inc. | 534.35 Million JPY | 318.167% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 576.193% |
| CellSeed Inc. | -836.51 Million JPY | -39.362% |